Author

A. M. Lopez

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. Gallegos· 1 shared A. M. Sockwell· 1 shared A. M. Soulika· 1 shared A. Maitra· 1 shared B. Li· 1 shared B. M. Moreno Diaz· 1 shared C. Hernandez· 1 shared C. Recendez· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioengineering

A. Gallegos

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Programmable delivery of fluoxetine via wearable bioelectronics for wound healing in vivo

H. Li, H.-y. Yang, N. Asefifeyzabadi, P. Baniya, K. Zlobina, H.-C. Hsieh, T. Nguyen, C. Hernandez, H. Carrion, M. Tebyani, J. Selberg, M. Gomez, M. Teodorescu, A. M. Lopez, A. Gallegos, , M. Rolandi

This paper introduces a wearable bioelectronic bandage that delivers fluoxetine on-demand to wounds, reducing inflammation and accelerating healing in mice.

bioRxiv · Oct 10, 2023Bioengineering

Oncogenic KrasG12D specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8+ T cells dependent manner

K. K. Mahadevan, K. McAndrews, V. LeBleu, S. Yang, H. Lyu, B. Li, A. M. Sockwell, M. L. Kirtley, S. J. Morse, B. M. Moreno Diaz, M. P. Kim, N. Feng, A. M. Lopez, P. A. Guerrero, H. Sugimoto, , R. Kalluri

This study shows that MRTX1133, a KrasG12D inhibitor, reduces early pancreatic lesions and, when combined with immunotherapy, regresses advanced PDAC by enhancing CD8+ T cell activity.

bioRxiv · Feb 15, 2023 · PreprintCancer Biology